Key Takeaways:
Definium Therapeutics reported positive Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder, with a 5.4-point placebo-adjusted HAM-A improvement (p<0.0001).
"The unprecedented efficacy demonstrated in Voyage should raise the bar for what patients and clinicians expect from GAD treatments," Rob Barrow, chief executive officer of Definium Therapeutics, said.
The trial enrolled 214 adults randomized 1:1 to a single 100 µg dose of DT120 ODT or placebo. The least-squares mean change in HAM-A at Week 12 was -11.6 for DT120 versus -6.2 for placebo, corresponding to a Cohen's d of 0.81. Efficacy appeared by Day 2 and was sustained at all post-baseline timepoints. Response rate (≥50% HAM-A improvement) reached 43 percent versus 16 percent on placebo, and remission (HAM-A ≤7) hit 14 percent versus 4 percent.
The readout marks Definium's second positive Phase 3 for DT120, following Emerge in major depressive disorder in June. Panorama, the second GAD Phase 3 study including a 50 µg dose arm, is expected to report topline results in September 2026, which could support an NDA submission. Shares rose 7.33 percent on the news.
DT120 ODT was generally well tolerated, with adverse events mostly mild to moderate, transient, and concentrated on the dosing day. No serious adverse events were reported in the DT120 arm, and no suicidality signal or suicidal behavior was identified. The average time to clear the end-of-session checklist was 6.4 hours, with 92 percent of participants meeting criteria by hour 8.
Brian Barnett, MD, vice chair of psychiatry at Cleveland Clinic and a Voyage principal investigator, said the last new FDA-approved treatment for GAD was nearly two decades ago, and many patients have not found relief despite trying multiple therapies. "A single-dose treatment option delivering meaningful benefits for 12 weeks is a promising step forward not found in today's therapies," he said.
The drug is a proprietary formulation of lysergide (LSD) using Catalent's Zydis ODT fast-dissolve technology. It acts as a partial agonist at serotonin-2A (5-HT2A) receptors and has received Breakthrough Therapy designation from the FDA for GAD. Definium is also developing DT120 for major depressive disorder and posttraumatic stress disorder.
GAD affects approximately 26 million U.S. adults, and the last new FDA-approved treatment for the condition was in 2007. Definium estimates a potential $2 billion revenue opportunity per 1 percent penetration across GAD and MDD based on internal analyses.
The positive Voyage readout, combined with the earlier Emerge results in MDD, gives Definium a data package spanning two indications with consistent effect sizes around d=0.8. Investors will watch the Panorama topline in September as the next resolution point for the GAD program, with a potential NDA submission following.
This article is for informational purposes only and does not constitute investment advice.
